Improvement and decline in vision with gene therapy in childhood blindness.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 25936984.
- Also identified by DOI 10.1056/NEJMoa1412965 and PMC identifier 4450362.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Retinal gene therapy for Leber's congenital amaurosis, an autosomal recessive childhood blindness, has been widely considered to be safe and efficacious. Three years after therapy, improvement in vision was maintained, but the rate of loss of photoreceptors in the treated retina was the same as that in the untreated retina. Here we describe long-term follow-up data from three treated patients. Topographic maps of visual sensitivity in treated regions, nearly 6 years after therapy for two of the patients and 4.5 years after therapy for the third patient, indicate progressive diminution of the areas of improved vision. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00481546.).
Medical subject headings
- Genetic Therapy
- Leber Congenital Amaurosis
- Photoreceptor Cells, Vertebrate
- Retina